SCHEMBL1277205

SCHEMBL1277205

C/C(=C\c1cccc(C)c1-c1ccc(O)cc1)C(=O)NC(=N)N

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.33
PREP P48147 2/20 0.32
CELA1 Q9UNI1 1/20 0.32
F10 P00742 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
SENP1 Q9P0U3 1/20 0.31
F2 P00734 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31
PLAT P00750 1/20 0.31
KLK1 P06870 1/20 0.31
KLK5 Q9Y337 1/20 0.31
FABP4 P15090 1/20 0.31
HSD17B1 P14061 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277410 0.88 HSD17B1 (0.34) HSD17B1MMP1MMP2MMP9ESRRG
SCHEMBL1277277 0.84 BACE1 (0.40) F10HSD17B1MMP9
SCHEMBL1277443 0.82 HSD17B1 (0.33) HSD17B1
SCHEMBL12709258 0.81 HSD17B1 (0.35) F10HSD17B1
SCHEMBL1278001 0.80 F10 (0.41) USP7F10KDM4EF2PLAU
SCHEMBL1277288 0.79 ALDH1A1 (0.44) F10KDM4EHSD17B1
SCHEMBL1277164 0.79 BACE1 (0.38) F10KDM4EHSD17B1
SCHEMBL1277249 0.79 F10 (0.36) USP7F10KDM4EF2HSD17B1
SCHEMBL1277438 0.78 SLC9A3 (0.40) F10KDM4EHSD17B1ESRRG
SCHEMBL1277366 0.78 HSD17B1 (0.33) USP7F10HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 USP7 3541/4885PREP 2576/4885CELA1 3381/4885
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 USP7 3541/4885PREP 2576/4885CELA1 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.